KR20140091543A - 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법 - Google Patents

전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법 Download PDF

Info

Publication number
KR20140091543A
KR20140091543A KR1020147011912A KR20147011912A KR20140091543A KR 20140091543 A KR20140091543 A KR 20140091543A KR 1020147011912 A KR1020147011912 A KR 1020147011912A KR 20147011912 A KR20147011912 A KR 20147011912A KR 20140091543 A KR20140091543 A KR 20140091543A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
composition
oxymetazoline
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147011912A
Other languages
English (en)
Korean (ko)
Inventor
워런 제이. 셰러
아서 클랩
필리프 안드레스
Original Assignee
갈데르마 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈데르마 소시에떼아노님 filed Critical 갈데르마 소시에떼아노님
Publication of KR20140091543A publication Critical patent/KR20140091543A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
KR1020147011912A 2011-10-19 2012-10-12 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법 Withdrawn KR20140091543A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161548844P 2011-10-19 2011-10-19
US61/548,844 2011-10-19
PCT/IB2012/002500 WO2013057579A2 (en) 2011-10-19 2012-10-12 Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors

Publications (1)

Publication Number Publication Date
KR20140091543A true KR20140091543A (ko) 2014-07-21

Family

ID=47631462

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147011912A Withdrawn KR20140091543A (ko) 2011-10-19 2012-10-12 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법

Country Status (13)

Country Link
US (1) US9744168B2 (enExample)
EP (1) EP2768502A2 (enExample)
JP (1) JP2014530846A (enExample)
KR (1) KR20140091543A (enExample)
CN (1) CN103889417A (enExample)
AU (1) AU2012324543B2 (enExample)
BR (1) BR112014009210A2 (enExample)
CA (1) CA2850273A1 (enExample)
IL (1) IL231820A0 (enExample)
MX (1) MX2014004383A (enExample)
PH (1) PH12014500783A1 (enExample)
RU (1) RU2014119879A (enExample)
WO (1) WO2013057579A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102122980B1 (ko) * 2018-12-28 2020-06-18 한국프라임제약주식회사 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
WO2015191917A1 (en) * 2014-06-11 2015-12-17 Allergan, Inc. Stabilized oxymetazoline formulations and their uses
WO2018065546A1 (en) * 2016-10-07 2018-04-12 Micreos Human Health B.V. Vasoconstricitve and antibacterial combination treatment for rosacea

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
DE2436882A1 (de) 1974-07-29 1976-02-19 Schering Ag Neue oxyphenylbutazon-derivate und ihre herstellung
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE2632678C2 (de) 1976-07-16 1986-02-27 Schering AG, 1000 Berlin und 4709 Bergkamen 6α-Fluor-12α-Halogen-Kortikoide und Verfahren zu ihrer Herstellung
NZ185295A (en) 1976-10-04 1980-04-28 Schering Ag 9-chloroprednisolone derivatives and pharmaceutical compositions
US4285967A (en) 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4908387A (en) 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
ES2187533T3 (es) 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
WO2000023066A2 (en) 1998-10-20 2000-04-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US5910312A (en) 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
SE9901295D0 (sv) 1999-04-13 1999-04-13 Jan Hedner Sätt och medel för att förebygga, behandla och diagnostisera kardiovaskulära komplikationer hos patienter med obstruktiv sömnapné
ES2199094T1 (es) 1999-08-19 2004-02-16 Lavipharm Sa Polimeros formadores de pelicula, procedimientos de uso y aplicaciones de los mismos.
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
CA2402405C (en) 2000-07-14 2008-02-12 Allergan Sales, Inc. Compositions containing alpha-2-adrenergic agonist components
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6680062B2 (en) 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
EP2230910A4 (en) 2007-12-21 2011-04-13 Galderma Lab Inc PRE-SURGICAL TREATMENT
KR20110017365A (ko) 2008-05-30 2011-02-21 페어필드 클리니컬 트라이얼즈 엘엘씨 피부 염증 및 변색을 위한 방법 및 조성물
WO2009152344A2 (en) * 2008-06-11 2009-12-17 Comgenrx, Inc. Combination therapy using phosphodiesterase inhibitors
EP2493475A4 (en) 2009-10-30 2014-10-29 Intratus Inc COSMETIC METHODS AND PREPARATIONS FOR THE PROLONGED RELEASE OF THERAPEUTIC AGENTS IN THE EYE
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102122980B1 (ko) * 2018-12-28 2020-06-18 한국프라임제약주식회사 들깨 잎 추출물을 유효성분으로 함유하는 갱년기 관련 안면홍조 완화용 조성물

Also Published As

Publication number Publication date
US20140343067A1 (en) 2014-11-20
RU2014119879A (ru) 2015-11-27
AU2012324543B2 (en) 2017-08-10
WO2013057579A2 (en) 2013-04-25
IL231820A0 (en) 2014-05-28
AU2012324543A1 (en) 2014-05-01
EP2768502A2 (en) 2014-08-27
PH12014500783A1 (en) 2014-05-12
WO2013057579A3 (en) 2013-07-04
JP2014530846A (ja) 2014-11-20
MX2014004383A (es) 2014-11-12
CN103889417A (zh) 2014-06-25
CA2850273A1 (en) 2013-04-25
US9744168B2 (en) 2017-08-29
BR112014009210A2 (pt) 2017-04-18

Similar Documents

Publication Publication Date Title
EP1631293B2 (en) Compounds, formulations, and methods for treating or preventing rosacea
EP2481412B1 (en) Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US20120282346A1 (en) Brimonidine compositions for treating erythema
US8440688B2 (en) Compounds, formulations and methods for reducing skin wrinkles, creasing and sagging
US20120082625A1 (en) Combination treatment for rosacea
AU2014292879A1 (en) Compositions for treating skin thickening
KR20140091543A (ko) 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
AU2012324544B2 (en) Method for treating capillary hemangiomas
EP2962689B1 (en) Method of treating flushing associated with carcinoid tumors and carcinoid syndrome
HK1164126B (en) Topical composition for use in the treatment of rosacea-induced redness
HK1204996B (en) Compounds, formulations, and methods for treating or preventing rosacea
HK1084591B (en) Compounds, formulations, and methods for treating or preventing rosacea

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140430

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid